‘Something was wrong’: Inside a Canadian biotech firm’s fight to prove ‘stock spoofing’ – CTV
November 26, 2025
In a lab east of Toronto, Dr. Andrzej Chruscinski’s team is testing a fine white powder that they believe could be a breakthrough in the treatment of a debilitating nerve disease.
As W5’s cameras watch, a lab technician places a sample inside an instrument that uses x-rays to test the product’s purity. A tell-tale pattern appears on a computer screen: one unique to the drug, called Lucid-MS.
“This is an important step in the quality control of our product,” said Chruscinski. He’s excited about the potential for Lucid-MS to treat multiple sclerosis, a disease that damages nerve coverings called myelin.
“Most drugs work for multiple sclerosis by inhibiting the immune system. Our drug is very different,” Chruscinski said. “It works by preventing the myelin from unraveling. It works on a totally different aspect of this disease.”
But in a series of interviews with W5, Quantum BioPharma executives say the lab work has not been the hardest part of getting Lucid-MS through clinical trials, on the way to patients.
